Sign in Subscribe
Cancer research

Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer

Strategic Insights

— 1 min read

Research from the Department of Medical Oncology at the Beijing Chest Hospital has shed new light on the prognostic value of dynamic C-reactive protein-to-lymphocyte ratio (CLR) in small cell lung cancer (SCLC) patients treated with chemoimmunotherapy. A retrospective study of 88 SCLC patients found a significant association between reduced CLR and improved objective response rate (ORR) and progression-free survival (PFS). The study suggests that CLR can serve as a potential biomarker for predicting the prognosis of SCLC patients treated with chemoimmunotherapy.

Key Takeaways:

  • The study investigated 88 SCLC patients who underwent chemoimmunotherapy between January 1st, 2020 and December 12th, 2022.
  • The association between C-reactive protein-to-lymphocyte ratio (CLR) and prognostic outcomes after chemoimmunotherapy was examined.
  • Patients with decreased CLR had significantly higher ORR, with odds ratios of 3.91 (P = 0.005).
  • Reduction of CLR after chemoimmunotherapy was associated with a significantly higher ORR and improved PFS.
  • Dynamic CLR can serve as a potential biomarker for predicting the prognosis of SCLC patients treated with chemoimmunotherapy.
  • Shuyan Sheng, Zhaozhen Wu, Hua Zheng, Hui Zhang, Quan Zhang, Zan Liu, Shouzheng Wang, Xi Li, Jie Li, Jialin Lv, and Ying Hu were involved in the study.
  • The study was published in the Journal of Inflammation Research, a peer-reviewed journal that focuses on inflammation research.

Statistics:

  • 88 SCLC patients were evaluated in the study.
  • The patients underwent chemoimmunotherapy between January 1st, 2020 and December 12th, 2022.
  • Patients with decreased CLR had a significantly higher ORR, with odds ratios of 3.91 (P = 0.005).
  • The study showed a significant association between reduced CLR and improved PFS.
  • The study was published in a peer-reviewed journal, the Journal of Inflammation Research, which is a member of the Dove Medical Press journals.

Sources:

  • Journal of Inflammation Research, 2025, Volume 18, Issue 1: 9343-9353 (http://www.dovepress.com/journal-of-inflammation-research-journal)
  • Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, and Beijing Tuberculosis and Thoracic Tumor Research Institute (Correspondence: Ying Hu, huying@bjxkyy.cn)
  • NewsRx. New Research on Lung Cancer from Department of Medical Oncology Summarized (Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer). TB & Outbreaks Week. August 5, 2025; p 3006.

Read more